Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mecobalamin + betamethasone is a combination therapy investigated for the management and prevention of postoperative chronic pain. Mecobalamin, a coenzyme form of vitamin B12, plays a critical role in nerve repair and myelination by acting as a cofactor for methionine synthase, which is essential for the synthesis of lecithin and the maintenance of the myelin sheath. Betamethasone is a potent, long-acting glucocorticoid that exerts strong anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, thereby inhibiting the production of pro-inflammatory cytokines and reducing local edema. In clinical settings, particularly those led by Xuzhou Cancer Hospital, this combination is often administered via local injection or nerve blocks (such as paravertebral blocks) to mitigate nerve injury-induced inflammation and promote neural recovery following surgeries like thoracoscopy, aiming to prevent the transition from acute to chronic pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mecobalamin + betamethasone.